VTVT insider transaction filings
vTv Therapeutics Inc. — 32 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-29. Screen VTVT transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 5 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 6.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP — Director & 667, L.P. — Director & Baker Brothers Life Sciences LP — Director & BAKER FELIX — Director & BAKER JULIAN — Director & Baker Bros. Advisors (GP) LLC — Director | 1 | — | — | 2 |
| AKKARAJU SRINIVAS — Director | 1 | — | — | 1 |
| Al-Marzooqi Fahed — Director | 1 | — | — | 1 |
| Phillips Anne M. — Director | 1 | — | — | 1 |
| SPIEGELMAN DANIEL K — Director | 1 | — | — | 1 |
Recent Form 4 filings — vTv Therapeutics Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-29 | 4 | Al-Marzooqi Fahed — Director | Grant/award (A): 6,000 (derivative) @ $35.08 | EDGAR |
| 2026-06-29 | 4 | Phillips Anne M. — Director | Grant/award (A): 6,000 (derivative) @ $35.08 | EDGAR |
| 2026-06-29 | 4 | AKKARAJU SRINIVAS — Director | Grant/award (A): 6,000 (derivative) @ $35.08 | EDGAR |
| 2026-06-29 | 4 | SPIEGELMAN DANIEL K — Director | Grant/award (A): 6,000 (derivative) @ $35.08 | EDGAR |
| 2026-06-29 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director Baker Bros. Advisors (GP) LLC — Director | Grant/award (A): 6,000 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Tung Michael Stephen — EVP & CFO | Grant/award (A): 44,969 (derivative) @ $36.92 | EDGAR |
| 2026-02-18 | 4 | SEKHRI PAUL J — Pres, CEO and Exec Chairperson, Director | Grant/award (A): 140,000 (derivative) @ $36.92 | EDGAR |
| 2025-09-25 | 4 | AKKARAJU SRINIVAS — Director | Grant/award (A): 106,000 @ $15.27 · Grant/award (A): 877,214 (derivative) · Grant/award (A): 983,214 (derivative) | EDGAR |
| 2025-09-05 | 4 | AKKARAJU SRINIVAS — Director | Grant/award (A): 655,523 (derivative) · Grant/award (A): 655,523 (derivative) | EDGAR |
| 2025-09-05 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director Baker Bros. Advisors (GP) LLC — Director | Grant/award (A): 4,308 · Grant/award (A): 46,692 · Grant/award (A): 217,144 (derivative) · Grant/award (A): 2,353,913 (derivative) · Grant/award (A): 221,452 (derivative) · Grant/award (A): 2,400,605 (derivative) | EDGAR |
| 2025-06-12 | 4 | Al-Marzooqi Fahed — Director | Grant/award (A): 4,000 (derivative) @ $16.59 | EDGAR |
| 2025-06-12 | 4 | Phillips Anne M. — Director | Grant/award (A): 4,000 (derivative) @ $16.59 | EDGAR |
| 2025-06-12 | 4 | AKKARAJU SRINIVAS — Director | Grant/award (A): 4,000 (derivative) @ $16.59 | EDGAR |
| 2025-06-12 | 4 | SPIEGELMAN DANIEL K — Director | Grant/award (A): 4,000 (derivative) @ $16.59 | EDGAR |
| 2025-06-12 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director Baker Bros. Advisors (GP) LLC — Director | Grant/award (A): 4,000 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | Tung Michael Stephen — EVP & CFO | Grant/award (A): 45,000 (derivative) @ $21.25 | EDGAR |
| 2025-04-24 | 4 | AKKARAJU SRINIVAS — Director | Grant/award (A): 2,250 (derivative) @ $17.22 · Grant/award (A): 983 (derivative) @ $17.22 | EDGAR |
| 2025-03-07 | 4 | SEKHRI PAUL J — Pres, CEO and Exec Chairperson, Director | Grant/award (A): 108,000 (derivative) @ $19.66 | EDGAR |
| 2024-12-06 | 4 | Samsara BioCapital GP, LLC — 10% owner Samsara BioCapital, L.P. — 10% owner | Other (J): 58,836 · Grant/award (A): 58,885 (derivative) | EDGAR |
| 2024-12-06 | 4 | AKKARAJU SRINIVAS — Director, 10% owner | Disposition to issuer (D): 58,836 · Grant/award (A): 58,885 (derivative) | EDGAR |
| 2024-11-19 | 4 | SEKHRI PAUL J — Pres, CEO and Exec Chairperson, Director | Purchase (P): 1,378 @ $16.35 · Purchase (P): 1,778 @ $16.88 · Purchase (P): 1,844 @ $16.96 | EDGAR |
| 2024-06-27 | 4 | Al-Marzooqi Fahed — Director | Grant/award (A): 3,000 (derivative) @ $17.22 | EDGAR |
| 2024-06-27 | 4 | Phillips Anne M. — Director | Grant/award (A): 2,250 (derivative) @ $17.22 · Grant/award (A): 860 (derivative) @ $17.22 | EDGAR |
| 2024-06-27 | 4 | SPIEGELMAN DANIEL K — Director | Grant/award (A): 6,000 (derivative) @ $17.22 | EDGAR |
| 2024-06-27 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director Baker Bros. Advisors (GP) LLC — Director | Grant/award (A): 6,000 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 · Grant/award (A): 983 (derivative) @ $0 · Grant/award (A): 983 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Al-Marzooqi Fahed — Director | Grant/award (A): 4,055 (derivative) @ $11.81 | EDGAR |
| 2024-06-13 | 4 | Tuch Steven L. — Chief Financial Officer | Grant/award (A): 62,159 (derivative) @ $11.81 | EDGAR |
| 2024-06-13 | 4 | Phillips Anne M. — Director | Grant/award (A): 3,750 (derivative) @ $16.04 | EDGAR |
| 2024-06-13 | 4 | SEKHRI PAUL J — President and CEO, Director | Grant/award (A): 89,212 (derivative) @ $11.81 | EDGAR |
| 2024-06-13 | 4 | AKKARAJU SRINIVAS — Director, 10% owner | Grant/award (A): 3,750 (derivative) @ $0 | EDGAR |
| 2024-03-07 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director Baker Bros. Advisors (GP) LLC — Director | Disposition to issuer (D): 4,776 @ $0 · Disposition to issuer (D): 52,881 @ $0 · Grant/award (A): 4,780 (derivative) @ $0 · Grant/award (A): 52,925 (derivative) @ $0 | EDGAR |
| 2024-02-29 | 4 | AKKARAJU SRINIVAS — Director, 10% owner | Grant/award (A): 224,732 @ $11.81 · Grant/award (A): 833,693 (derivative) @ $11.80 | EDGAR |
Recent 8-K events — vTv Therapeutics Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-13 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-10 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2025-12-19 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VTVT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →